Urielle is a women’s medical startup creating a smart adhesive catheter patch for female passive urine collection. Designed for bedridden, cognitively or mobility-impaired women, the non-invasive, single-use, power-free device aims to reduce catheter-associated urinary tract infection (CAUTI) risk and provide an alternative to indwelling catheters. Current external female urinary collection solutions suffer from leakage, skin irritation, and discomfort, contributing to CAUTIs, which cause significant health issues and increase healthcare costs. Urielle multi-layered design combines medical-grade, hypoallergenic materials, including a skin-friendly adhesive base, absorbent foam, micro-channeled collector, and breathable barrier film. It manages moisture, containment, and flexible fixation, adapting to female anatomy without external power or suction. The patch supports patient dignity and autonomy by minimizing leakage, odor, skin sores, irritation, pain, and nighttime disturbances. Preclinical data suggest a potential 50% CAUTI reduction, pending clinical validation. Urielle targets the growing German urinary catheter market, projected to rise from 247 million € (2021) to 393 million € (2031), with the external catheter segment growing at 5.3% CAGR. The company leverages Germany’s medical technology ecosystem, reimbursement pathways, and collaborations. Regulatory plans include EU MDR Class IIa and FDA Class I (510(k)-exempt) clearance by 2027. Led by experts in medical devices, microbiology, regulation, and business development from Israel and Germany, Urielle focuses on direct hospital sales and B2B partnerships, aiming for cost-effective production with strong margins. Future developments include IoT-enabled sensors for digital health monitoring. Urielle addresses infection prevention, antimicrobial resistance, and healthcare efficiencies, offering a novel innovation with meaningful impact on female urinary health worldwide.